PURPOSE: To evaluate the safety and clinical activity of mirvetuximab soravtansine, an antibody-drug conjugate comprising a humanized anti-folate receptor alpha (FRα) monoclonal antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent, in combination with bevacizumab in patients with FRα-positive, platinum-resistant ovarian cancer. METHODS: Patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer were administered mirvetuximab soravtansine (6 mg/kg, adjusted ideal body weight) and bevacizumab (15 mg/kg) once every 3 weeks. Eligibility included FRα positivity by immunochemistry and prior bevacizumab exposure was permitted. Adverse events, tumor response, and progression-f...
Purpose: Preclinically, AKT kinase inhibition restores drug sensitivity in platinum-resistant tumors...
PURPOSE: The single-arm OCTAVIA study evaluated front-line bevacizumab plus weekly paclitaxel and q3...
Farletuzumab is a humanized monoclonal antibody that binds to folate receptor-α, which is highly exp...
PURPOSE: To evaluate the safety profile and preliminary antitumor activity of mirvetuximab soravtans...
Background Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate comprising a folate recept...
Resistance to platinum-based therapy poses a significant clinical challenge for the management of ad...
Mirvetuximab soravtansine, an antibody-drug conjugate that binds with high affinity to folate recept...
PURPOSE: The vascular disrupting agent fosbretabulin tromethamine selectively targets pre-existing t...
PURPOSE: Bevacizumab (BV) monotherapy leads to compensatory upregulation of multiple signaling pathw...
AbstractElevated folate receptor alpha (FRα) expression is characteristic of epithelial ovarian canc...
Purpose: This study assessed the efficacy, safety, and pharmacokinetics of adavosertib in combinatio...
PURPOSE: This was a multinational, open-label, randomized phase III trial comparing yttrium-90-label...
PURPOSE: Combination therapies targeting immunological checkpoints have shown promise in treating mu...
Hiroyuki Yoshida, Akira Yabuno, Keiichi FujiwaraDepartment of Gynecologic Oncology, Saitama Medical ...
Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial growth factor and...
Purpose: Preclinically, AKT kinase inhibition restores drug sensitivity in platinum-resistant tumors...
PURPOSE: The single-arm OCTAVIA study evaluated front-line bevacizumab plus weekly paclitaxel and q3...
Farletuzumab is a humanized monoclonal antibody that binds to folate receptor-α, which is highly exp...
PURPOSE: To evaluate the safety profile and preliminary antitumor activity of mirvetuximab soravtans...
Background Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate comprising a folate recept...
Resistance to platinum-based therapy poses a significant clinical challenge for the management of ad...
Mirvetuximab soravtansine, an antibody-drug conjugate that binds with high affinity to folate recept...
PURPOSE: The vascular disrupting agent fosbretabulin tromethamine selectively targets pre-existing t...
PURPOSE: Bevacizumab (BV) monotherapy leads to compensatory upregulation of multiple signaling pathw...
AbstractElevated folate receptor alpha (FRα) expression is characteristic of epithelial ovarian canc...
Purpose: This study assessed the efficacy, safety, and pharmacokinetics of adavosertib in combinatio...
PURPOSE: This was a multinational, open-label, randomized phase III trial comparing yttrium-90-label...
PURPOSE: Combination therapies targeting immunological checkpoints have shown promise in treating mu...
Hiroyuki Yoshida, Akira Yabuno, Keiichi FujiwaraDepartment of Gynecologic Oncology, Saitama Medical ...
Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial growth factor and...
Purpose: Preclinically, AKT kinase inhibition restores drug sensitivity in platinum-resistant tumors...
PURPOSE: The single-arm OCTAVIA study evaluated front-line bevacizumab plus weekly paclitaxel and q3...
Farletuzumab is a humanized monoclonal antibody that binds to folate receptor-α, which is highly exp...